
**Therapeutic monitoring of TNF-alpha inhibitors in
rheumatoid arthritis [DAR17/10/02]**

Addendum #2

Sensitivity analysis: adalimumab acquisition cost

21 January 2019

This addendum was produced in response to a request from the NICE Technical Team for the Assessment Group (AG) to conduct one-way deterministic sensitivity analyses on the adalimumab (ADL) acquisition cost by applying different percentage discounts to the price of ADL.

One-way deterministic sensitivity analyses were conducted based on data from Ucar and colleagues (2017)(1) and Arango and colleagues (2017)(2) in which the ADL acquisition cost was varied (-20%, -40%, -60%, -80%) (Table 1).

Table 1: One-way deterministic sensitivity analyses: ADL acquisition cost

Parameter	Assumption	Intervention vs. Control		ICER	Source
		Costs	QALYs		
ADL acquisition cost	-20%	-£251	0.007	-£36,868 Intervention dominates Standard care	Ucar and colleagues (2017)
	-40%	-£243	0.007	-£35,586 Intervention dominates Standard care	Ucar and colleagues (2017)
	-60%	-£234	0.007	-£34,303 Intervention dominates Standard care	Ucar and colleagues (2017)
	-80%	-£225	0.007	-£33,021 Intervention dominates Standard care	Ucar and colleagues (2017)
	-20%	£377	-0.007	-£55,637 Standard care dominates intervention	Arango and colleagues (2017)
	-40%	£392	-0.007	-£57,900 Standard care dominates intervention	Arango and colleagues (2017)
	-60%	£407	-0.007	-£60,162 Standard care dominates intervention	Arango and colleagues (2017)
	-80%	£422	-0.007	-£62,424 Standard care dominates intervention	Arango and colleagues (2017)

Key: ADL: adalimumab; ICER: incremental cost-effectiveness ratio

Regardless of the assumed reduction in ADL acquisition costs, using data from Ucar and colleagues (2017)(1) the intervention was estimated to dominate standard care and using data from Arango and colleagues (2017)(2) standard care was estimated to dominate the intervention.

References

1. Ucar E, Gorostiza I, Gomez C, Perez C, Dios J, Alvarez B, et al. Prospective, intervention, multicenter study of utility of biologic drug monitoring with respect to the efficacy and cost of adalimumab tapering in patients with rheumatic diseases: preliminary results of ingebio study. Annals of the rheumatic diseases Conference: annual european congress of rheumatology, EULAR 2017 Spain [Internet]. 2017; 76(Supplement 2):[826 p.]. Available from: <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/706/CN-01467706/frame.html>.
2. Arango CG, Vivar MLG, Angulo EU, Gorostiza I, Perez CE, De Dios JR, et al. Prospective, intervention, multicenter, non-inferiority study of utility of therapeutic drug monitoring with respect to the efficacy and cost of adalimumab tapering in patients with rheumatic diseases. Arthritis and Rheumatology Conference: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP. 2017;69(Supplement 10).